Including spinal cord injury more.

Geron is a biopharmaceutical company developing first-in – class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are on our core competencies in telomerase and human embryonic stem cells more . Information, please visit information, please visit.

.nnounces issuance of U.S. Patent for Cardiomyocytes from human embryonic stem Geron Corporation today announced the issuance of U.S. Patent No. With broad claims to cardiomyocytes from human embryonic stem cells are derived. The patent runs until at least April 2025 . Geron GRNCM1 program developed hESC-derived cardiomyocytes for the treatment of heart disease.

With low-dose Institute Physicians – Scientist Posted is less toxic cancer treatment for chronic lymphocytic leukemia.

Nevada Cancer Institute research and oncologist Kenneth A. Had a paper in the 1 st Issued in Feb. 2009 edition. Of the Journal of Clinical Oncology has a new, highly potent new treatment for chronic lymphocytic leukemia Director of the of leukemia part at NVCI been succeed recruit to the institution from of University of Pittsburgh Cancer Centre last summer. Than the investigator, Dr. Foon takes the the latest therapies out of the laboratory to the patient. Add this paper entitled ‘chemoimmunotherapy treatment with low-dose fludarabine and cyclophosphamide and high dose rituximab with previously untreated chronic lymphocytic leukemia,’has recently been published in the magazine, Journal of Clinical Oncology , and was also version of the journal version of the journal.